CKD-348 + CKD-828 + D097 + D337

This is an **oral fixed-dose combination therapy** under investigation, composed of the small molecule drugs CKD-348, CKD-828, D097, and D337. The combination is primarily being developed for the treatment of **hypertension and dyslipidemia** in adult patients. Multiple phase I clinical trials have evaluated its **pharmacokinetics, tolerability, and safety** in comparison both to CKD-348 monotherapy and to co-administration of the other three components. Clinical trials indicate it is intended for cardiovascular and metabolic diseases, targeting both blood pressure control and lipid modulation. The developer and lead sponsor for all listed trials is Chong Kun Dang Pharmaceutical. The specific mechanisms of action, targets, and molecular modalities of each component are not disclosed in available sources[1][2][3][4][6].

Other names

CKD-348CKD348CKD 348CKD-828CKD828CKD 828D097D-097D 097D337D-337D 337